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Unlike numerous pore-forming amphiphilic peptide
antibiotics, the lantibiotic nisin is active in nanomolar
concentrations, which results from its ability to use the
lipid-bound cell wall precursor lipid II as a docking
molecule for subsequent pore formation. Here we use
genetically engineered nisin variants to identify the
structural requirements for the interaction of the pep-
tide with lipid II. Mutations affecting the conformation
of the N-terminal part of nisin comprising rings A
through C, e.g. [S3T]nisin, led to reduced binding and
increased the peptide concentration necessary for pore
formation. The binding constant for the S3T mutant was
0.043 3 107 M21 compared with 2 3 107 M21 for the wild-
type peptide, and the minimum concentration for pore
formation increased from the 1 nM to the 50 nM range. In
contrast, peptides mutated in the flexible hinge region,
e.g. [DN20/DM21]nisin, were completely inactive in the
pore formation assay, but were reduced to some extent
in their in vivo activity. We found the remaining in vivo
activity to result from the unaltered capacity of the
mutated peptide to bind to lipid II and thus to inhibit its
incorporation into the peptidoglycan network. There-
fore, through interaction with the membrane-bound cell
wall precursor lipid II, nisin inhibits peptidoglycan syn-
thesis and forms highly specific pores. The combination
of two killing mechanisms in one molecule potentiates
antibiotic activity and results in nanomolar MIC values,
a strategy that may well be worth considering for the
construction of novel antibiotics.
The antimicrobial peptide nisin is produced by numerous
strains of Lactococcus lactis and inhibits a broad range of
Gram-positive bacteria (1, 2). It belongs to the lantibiotics, a
group of antimicrobial peptides that is characterized by the
presence of intramolecular rings formed by the thioether amino
acids lanthionine and 3-methyllanthionine (3, 4). Nisin has had
a long history as a potent and safe food preservative, although
recent insight into the molecular mechanism of its bactericidal
activity also make it interesting for biomedical applications (5,
6). Generally, the nisin-type subgroup of lantibiotics comprises
elongated cationic peptides that have the capacity to adopt
amphiphilic structures. Such peptides are assumed to kill mi-
crobes by disturbing the integrity of the energy-transducing
membrane. Indeed, early experiments demonstrated that nisin
or related lantibiotics induced rapid efflux of ions or cytoplas-
mic solutes such as amino acids and nucleotides. The concom-
itant depolarization of the cytoplasmic membrane resulted in
an instant termination of all biosynthetic processes (7, 8).
Structural analysis in the presence of micelles indicated that
the hydrophilic groups of the peptide interact with the phos-
pholipid headgroups, and the hydrophobic side chains are im-
mersed in the hydrophobic core of the membrane (9, 10). The
wedge model as proposed by Driessen et al. (11) takes into
account such structural data and proposes that the peptides
insert into the membrane without losing contact with the mem-
brane surface, resulting in the formation of a short-lived pore.
Whereas the wedge model may illustrate results obtained
with model membranes, a number of effects observed with
intact living cells remain unexplained; in particular, the fact
that nisin acts on model membranes at micromolar concentra-
tions whereas in vivo minimal inhibitory concentration (MIC)1
values are in the nanomolar range. The discrepancies were
explained by the finding that nisin and epidermin use lipid II,
the bactoprenol-bound precursor of the bacterial cell wall as a
docking molecule for subsequent pore formation (12). The spec-
ificity of the nisin-lipid II interaction and the resulting high
level activity of nisin was demonstrated in a comparative study
with the pore-forming amphiphilic defense peptide magainin 2
(5). We found that, in contrast to magainin, the activity of nisin
is enhanced by a factor of 103 when lipid II is available for
targeted pore formation. The fact that nisin specifically binds
to lipid II was particularly remarkable, because previously
mersacidin and actagardine from the type B class of lantibiotics
also had been shown to form a complex with the cell wall
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precursor. In this case however, binding only blocked the pre-
cursor from incorporation into polymeric peptidoglycan (13,
14). We therefore assumed that lantibiotics may have defined
lipid II binding motifs that could represent interesting lead
compounds for the development of novel antibiotics. In partic-
ular, these lantibiotics are active against the Gram-positive
bacteria that are most prominent with regard to resistance
development, e.g. Staphylococci and Enterococci.
Here we studied the interaction between lipid II and a num-
ber of nisin mutant peptides to identify the structural elements
of the nisin molecule that are important for the interaction
with lipid II and subsequent pore formation. Surprisingly, we
identified nisin mutant peptides that were unable to form pores
but retained considerable antimicrobial activity through block-
ing lipid II from incorporation into peptidoglycan. Thus nisin is
a dual-function antibiotic with two killing mechanisms com-
bined into one molecule.
EXPERIMENTAL PROCEDURES
Chemicals and Materials—All chemicals were of analytical grade or
better. The phospholipids 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) were
purchased from Avanti Polar Lipids, Inc. and stored at 220 °C in a 9:1
chloroform/methanol solution. Carboxyfluorescein (CF) was purchased
from Kodak and purified as described previously (15). Protein concen-
tration was determined using the bicinchonic acid protein assay rea-
gent (Pierce Chemical Corp.) with bovine serum albumin as a standard.
Nisin Z and Nisin Mutants—Nisin Z (16) and prepeptide nisin Z with
the N-terminal leader sequence of subtilin (17) as well as all mutant
peptides (18) were produced in SPYS medium (3% sucrose, 1% peptone
(Difco), 1% yeast extract (Difco), 0.2% NaCl, 0.002% MgSO4, and 1%
KH2PO4, pH 6.8). Peptides were purified from supernatants by hydro-
phobic-interaction chromatography using Fractogel TSK butyl 650-M
(Tosohaas), followed by preparative reversed phase-HPLC using aceto-
nitrile and 0.1% trifluoroacetic acid as eluents. Mutations were verified
by mass spectroscopy. Nisin Z is a natural variant of nisin A that only
differs in one single residue (Asn instead of His at position 27) and
possesses almost identical antimicrobial properties (19, 20). The [DN20/
DM21]nisin A, [S3T]nisin Z, [M17K]nisin Z, and [N20P/M21P]nisin A
(21) and the charged mutants [V32E]nisin Z and [V32K]nisin were
obtained by site-directed mutagenesis. Mutations of the structural
genes nisA or nisZ were performed by two successive polymerase chain
reactions, and mutated genes were expressed in L. lactis NZ9800 as
described previously (18). Nisin stock solutions were stored at 280 °C in
0.05% acetic acid. The MIC was determined by the inhibition of growth
of the indicator strains Micrococcus flavus DSM 1790 and Streptococcus
thermophilus Rs in a liquid bioassay (16, 18).
Lipid II Synthesis—Lipid II was synthesized in vitro using mem-
brane preparations of Micrococcus luteus ATCC 4698. Membranes were
isolated from lysozyme-treated cells by centrifugation (40,000 3 g),
washed twice in 50 mM Tris-HCl, 10 mM MgCl2, pH 7.5 and stored under
liquid nitrogen. For extraction and purification, the protocol elaborated
by Bro¨tz et al. (14) for [14C]lipid II was applied. The unlabeled lipid II
generated for the present study was detected by exploiting its ability to
form a complex with mersacidin. Aliquots of the respective chromato-
graphic fractions were added to a mersacidin activity test (12), and
those fractions that were able to antagonize mersacidin activity were
collected. The lipid II concentration in stock solutions was determined
by quantitative analysis of amino acids and amino sugars using the
o-phthaldialdehyde (OPA) derivatization technique (22). Lipid II sam-
ples were hydrolyzed in sealed tubes with 6 N HCl at 110 °C for 18 h.
After evaporation of HCl, amino acids and sugars were taken up in 200
mM borate buffer, pH 9.5 and derivatized with OPA. The derivatives
were separated by reversed-phase C18 HPLC chromatography using 50
mM phosphate buffer, pH 6.5 (buffer A) and methanol/tetrahydrofuran
(97:3) as eluent B. Fluorescence of the derivatives was recorded at 450
nm (excitation at 340 nm) and quantitated using appropriate stand-
ards. Purified lipid II was stored in chloroform/methanol (1:1, v/v) at
220 °C.
Preparation of Vesicles—Large unilamellar vesicles for the binding,
CF efflux, and potassium efflux experiments were prepared by the
extrusion technique (23) and treated as described previously (24). Ves-
icles were made of DOPC with or without 0.065 mol % lipid II (referring
to the total amount of lipids). Phospholipid was determined as inorganic
phosphate after treatment with perchloric acid (25).
CF-loaded vesicles were prepared with 50 mM CF and then diluted in
1.25 ml of K1 buffer (50 mM Mes-KOH, pH 6.0, 100 mM K2SO4) in a final
concentration of 25 mM phospholipid (on a phosphorous base). After
addition of wild-type or mutant nisin, the induced leakage was moni-
tored for 3 min. The increase of fluorescence intensity was measured at
515 nm (excitation at 492 nm) on a SPF 500C spectrophotometer (SLM
instruments Inc.) at 20 °C. The nisin-induced CF leakage was ex-
pressed relative to the total amount of CF released after lysis of the
vesicles by addition of 10 ml of 20% Triton X-100.
Potassium-loaded vesicles were prepared with KCl buffer (150 mM
KCl, 30 mM Mes, 20 mM Tris, pH 6.5). The vesicles were added to 5 ml
of buffer (30 mM Mes, 20 mM Tris, pH 6.5, 150 mM choline chloride) in
a final concentration of 25 mM phospholipid. Nisin or nisin mutant-
induced leakage was monitored with a K1 selective electrode (15-K,
Philips) and a reference electrode (R44/2, Philips). The total amount of
K1 in the vesicles was determined after addition of 20 ml of a 20%
solution of N,N-dimethyldodecylamine N-oxide (Fluka). Leakage was
expressed relative to the total amount of K1. The electrodes were
calibrated by titrating known amounts of potassium.
Radioactive Labeling—Radioactive labeling of nisin and binding ex-
periments were performed as described previously by Breukink (24).
Nisin Z, [S3T]nisin Z and [DN20/DM21]nisin A were 14C-labeled by
reductive methylation of the e-amino group of the lysine residues ac-
cording to the method of Dottavio-Martin and Ravel (26). The resulting
preparations had specific activities of 4.6 3 104, 8.2 3 104, and 13.3 3
104 dpm/nmol, respectively. The radiolabeled peptides were stored in
0.05% (v/v) acetic acid at 280 °C. The binding of the [14C]nisin Z and
variants was determined under equilibrium conditions. Vesicles (160
mM, on a phosphorus base) made of DOPC with 4% DOPG or with 0.5
mol % lipid II were incubated at room temperature with 14C-labeled
peptide in 0.5 ml of buffer (25 mM Mes, pH 6.0, 50 mM K2SO4) for 5 min.
The mixture was then centrifuged at 430,000 3 g for 45 min to spin
down the vesicles with the bound nisin Z. The amount of unbound nisin
in the supernatant and of vesicle-bound nisin in the pellet was deter-
mined by scintillation counting. No phosphate could be detected in the
supernatant after the centrifugation steps, and 90–100% of the applied
radioactivity was recovered. The binding isotherms of the nisin-lipid II
interaction could be well described by the Langmuir adsorption model
assuming that lipid II was the only binding site for nisin in the context
of DOPC vesicles.
In Vitro Peptidoglycan Synthesis—A crude membrane fraction was
prepared from Escherichia coli TB1 by disruption of exponentially
growing cells with a Branson Sonifier 250 (Danburry CT) twice for 3–5
min, 50% cooling phase and power level 5. Membranes were collected by
centrifugation (40,000 3 g), then washed and resuspended in buffer (50
mM Tris HCl, pH 7.5), to give a protein concentration of 8 mg/ml.
UDP-N-acetylmuramylpentapeptide (UDP-MurNAc-pentapeptide) was
isolated from Staphylococcus simulans 22. To accumulate the murein
precursor, exponentially growing cells were supplemented with 5 mg/ml
vancomycin and incubated for 30 min. After centrifugation, cells were
resuspended in distilled water (0.1 g/ml) and extracted by stirring the
suspension slowly into 2.5 volumes of boiling water. After 15 min, the
suspension was cooled, the cell debris removed (48,000 3 g) and the
supernatant lyophilized. The lyophilized material was then dissolved in
water and brought to pH 2 with 20% H3PO4. After acidification, pre-
cipitated material was removed by centrifugation, and the supernatant
fractionated on reversed-phase C18 HPLC under isocratic conditions (50
mM NaH2PO4, pH 5.2). The UDP-MurNAc-pentapeptide was identified
by mass spectrometry. For cell wall biosynthesis assays (35), it was
applied in 0.2 mM concentrations together with membranes (160 mg of
protein), 0.05 mM [14C]UDP-GlcNAc and 15–60 mM nisin peptides in a
total volume of 60 ml of membrane suspension buffer (50 mM Tris-HCl,
pH 8, 10 mM MgCl2, 1 mM mercaptoethanol). Incubation proceeded for
45 min at 32 °C before the reaction was stopped by heating (100 °C,
30 s). Aliquots were analyzed by paper chromatography (paper GB 002,
Schleicher und Schu¨ll, Dassel, Germany) in isobutyric acid/1 M NH4OH
(5:3, v/v). Polymeric peptidoglycan does not migrate from the starting
point, and the respective area was cut out and counted in a b-scintilla-
tion counter (1900 CA Tri-Carb scintillation counter, Packard, Zu¨rich).
RESULTS
Activity of Wild-type Nisin Z on Lipid II-containing Unila-
mellar Vesicles—Previous studies had shown that nisin in low
concentrations can induce rapid efflux of CF from multilamel-
lar liposomes when supplemented with 0.1 mol % lipid II. In
the absence of lipid II, such liposomes were not affected by
nisin concentrations as high as 1.25 mM (12). To characterize in
Lipid II-mediated Duality in the Activity of Nisin 1773
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detail the lipid II effect, we used unilamellar vesicles doped
with 0.065 mol % of the cell wall precursor. At 5 nM nisin,
significant dye release was observed, and ;60% release was
achieved with 50 nM nisin (Fig. 1A). Because dye efflux reached
a plateau within less than a minute, we plotted the percentage
of dye released after 1 min for a closer inspection of the con-
centration dependence of the nisin pore formation. Fig. 1B
demonstrates that upon the incorporation of lipid II, the sen-
sitivity of DOPC (1,2 dioleoyl-sn-glycero-3-phosphocholine) li-
posomes increased by three orders of magnitude. CF release
started at about 1 nM of the lantibiotic, whereas more than 1 mM
nisin was necessary to affect DOPC liposomes without lipid II.
In accordance with previous studies in the absence of lipid II
(24), membranes containing the negatively charged lipids
DOPG were considerably more sensitive (Fig. 1B) than the
DOPC liposomes. However, the difference in sensitivity disap-
peared after incorporation of 0.065 mol % lipid II (Fig. 1C).
Although the overall activity of nisin toward lipid II-containing
liposomes was relatively independent from the phospholipid
composition, slightly higher release rates were obtained with
DOPC as the bulk phase constituent. Under the test conditions
applied, the maximum marker release was achieved with nisin
concentrations in the range of 0.05 to 0.1 mM (Fig. 1C). Appli-
cation of higher concentrations reduced the dye release effi-
ciency with the DOPC liposomes and with the DOPC/DOPG
mixture. With DOPG vesicles, the dye-release rate increased
again at 1 mM, which agrees well with the results depicted in
Fig. 1B, because it coincides with the onset of the marker
release activity in the absence of lipid II.
Similar to the dependence of pore formation on peptide con-
centration, dye release was also dependent on the lipid II
concentration in liposomes (Fig. 1D). In a lipid II titration
series in which the nisin concentration was kept constant at 10
nM or 100 nM, efflux started at 0.001 mol % lipid II, i.e. for an
average liposome of 400 nm in diameter and 7 3 105 bulk lipid
molecules (of 0.70 nm2), only seven lipid II molecules per ves-
icle were sufficient to promote dye release. With increasing
peptide concentrations, the release activity reached an opti-
mum, in this case at ;0.1 mol %, and decreased with greater
lipid II concentrations. The presence of an optimum in the
curves obtained in both titration series suggests that there is
an optimal lipid II to peptide ratio, which may be in the range
of 1:1, e.g. at 0.1 mol % lipid II (optimum in Fig. 1D) the ratio
is 1.0:0.4 (lipid II to nisin) for 10 nM nisin, or 1:4 for 100 nM
nisin, respectively.
We also replaced the negatively charged CF with K1 to
detect indications for ion selectivity of the pore. Interestingly,
the efflux rates did not significantly differ with both markers
(e.g. Fig. 2; 90% K1 release after 1 min with 100 nM nisin). The
absence of ion selectivity of nisin pores formed in lipid II-doped
membranes stands in contrast to data obtained without lipid II
(24) and suggests that lipid II not only enhances the pore
formation activity of nisin but also has an influence on the pore
architecture.
Binding Characteristics of Nisin Z to Lipid II-containing
Liposomes—Membrane poration by cationic amphiphilic pep-
tides is considered a sequential process that includes binding to
the target membrane, insertion into the membrane, and the
formation of a functional pore. Detailed studies with various
model peptides (27) and with nisin Z (24) demonstrate that
lipids with a net negative charge, such as DOPG, are important
for binding via electrostatic interactions (24). Nisin, for exam-
ple, was bound stoichiometrically to one DOPG molecule per
positively charged amino acid residue. In contrast, very little
nisin was bound by pure DOPC liposomes, and the above data
(Fig. 1C) illustrate that DOPG is not essential when lipid II
serves as a specific target. We therefore studied the binding
behavior of radiolabeled nisin to DOPC liposomes supple-
mented with lipid II. With lipid II present in 0.5 mol %, nisin
showed a binding behavior that was best described by the
Langmuir adsorption model with an apparent minimal binding
constant of 2 3 107 M21 (Fig. 3).
The data shown in Fig. 3 indicate that nisin binding satu-
rates when each lipid II molecule is loaded with one nisin Z
molecule, indicative of a 1:1 binding stoichiometry, which
agrees well with the optimum curves obtained in the peptide
and lipid II titration experiments (Fig. 1D). A 1:1 stoichiometry
requires that all lipid II is available for binding; however, the
procedure for preparation of lipid II-containing liposomes is
very likely to result in a symmetric distribution of lipid II
headgroups with regard to the bilayer; i.e. only 50% of the
incorporated lipid II molecules should be outwardly orientated.
However, recent experiments with C-terminal His-tagged nisin
Z convincingly demonstrate that the lantibiotic is able to trans-
locate across a negatively charged lipid-containing membrane
(28). In light of these results it seems likely that in the presence
of lipid II, nisin can translocate across the membrane and thus
the inwardly orientated lipid II becomes available for interac-
tion with nisin.
Structural Requirements for the Lipid II-mediated Pore For-
mation—We used the DOPC/0.065 mol % lipid II vesicle system
to identify the structural elements in the nisin molecule that
are important for the interaction with lipid II and/or subse-
quent pore formation. Structure-function studies with nisin
and other lantibiotics had identified various structural features
important for the bactericidal activity in vivo or for activities in
in vitro systems. For instance, the C-terminal part of nisin is
important for binding to membranes with a negative surface
charge (24) and the two C-terminal amino acids (at positions 33
and 34) are not essential for the activity in vivo (29). In con-
trast, a short flexible region in the central part of the molecules
was found to be indispensable not only in nisin and other type
A lantibiotics (21) but also of unmodified peptide antibiotics
(30). Moreover, strong hints for an important role of the N-
terminal double ring system for binding to lipid II came from
structural comparison of several type A lantibiotics in a previ-
ous study (12). Based on these considerations we selected a
number of mutants in the respective regions of nisin (Fig. 4)
and compared their activities in the lipid II-containing lipo-
some system to their MIC values for M. flavus and S. ther-
mophilus (Table I).
Mutants with Charge Differences—Introduction of a charged
residue in position 32 only slightly reduced K1 release (Fig. 2)
and CF release activities (Fig. 5A) at low peptide concentra-
tions, regardless of whether Val-32 was replaced by a Lys or a
Glu residue. Similarly, only minor effects were observed in
vivo. A strong reduction of the activity of nisin in the liposome
assay by almost two orders of magnitude was observed when a
Lys residue was introduced into ring C of the peptide (Fig. 5A,
M17K), demonstrating that for pore formation a charged resi-
due is not tolerable in the central segment of the molecule.
However, in vivo, the M17K peptide lost only 50% of its activity
against M. flavus (Table I), which may be explained by the
particular role of anionic cell wall polymers in the overall
activity of cationic peptides (see “Discussion”).
Hinge Region Mutants—An even more drastic effect on the
activity was found for the hinge region mutants (Fig. 5B). In
[DN20/DM21]nisin, the flexible segment that connects rings C
and D is shortened to just one residue; this peptide did not
release more than 20% of the dye even when tested in concen-
trations higher than 1 mM. Replacement of both residues with
two prolines [N20P/M21P]nisin reduced the dye release to a
Lipid II-mediated Duality in the Activity of Nisin1774
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maximum of ;10%. [M21G]Nisin was slightly less impaired;
however, the 10% efflux obtained at 0.01 mM could not be
increased by raising the concentration of the peptide. Although
the in vivo activities of the hinge region mutants were also
reduced, the effect was comparatively less drastic for M. flavus.
However, for S. thermophilus, the MIC values increased by a
factor of 25, 40, and 2 for [N20P/M21P]nisin A, [DN20/
DM21]nisin A, and [M21G]nisin Z, respectively.
N-terminal Mutants—Because nisin-(1–12) covering the N-
terminal rings A and B had been reported to antagonize bind-
ing of wild-type nisin to target cells (31) it was especially
interesting to study peptides mutated in this segment of the
lantibiotic. However, nonconservative mutations in rings A and
B, which could have an impact on the structure of the rings and
thus be valuable tools for this study, are apparently incompat-
ible with the biosynthesis machinery and could not be produced
(21, 32). We tested three peptides in which the Dhb (i.e. the Thr
in the prepeptide) in position 2 was replaced by Ser, Ala, and
Val, respectively. These mutations had little effect on the MIC
and were slightly less active than wild-type nisin Z on lipid
II-containing liposomes (Fig. 5C). In contrast, a strong effect
was observed with [S3T]nisin. The S3T mutation results in the
formation of a 3-methyllanthionine ring instead of a lanthio-
nine ring and was found to exert relatively little influence on
the activity of the mutant peptide when tested on pure PG-
liposomes without lipid II (data not shown). However, with a
MIC of 39 nM against M. flavus, this peptide was considerably
less active in vivo.
The apparent discrepancy between the activity of [S3T]nisin
in vivo and in vitro disappeared when lipid II was incorporated
into the liposomes. Similar to the activity of the mutant peptide
against bacterial cells, its dye releasing activity was strongly
FIG. 1. Activity of nisin against lipid II-containing liposomes.
A, time course of nisin-induced leakage of CF from DOPC vesicles with
0.065 mol % lipid II. After ;30 s, 0.05 mM nisin Z (A) and 0.005 nisin Z
(B) was added, and the CF efflux was recorded. The 100% leakage level
was determined by addition of Triton X-100 after 180 s. The vesicle
concentration was 25 mM on a Pi basis. B, concentration dependence of
nisin Z-induced CF leakage from DOPC vesicles with 0.065 mol % lipid
II (f), pure DOPG vesicles (E), and pure DOPC vesicles (M). Addition of
nisin in a concentration of 0.015 mM to vesicles with lipid II results in
50% leakage. A similar extent of leakage from pure DOPG vesicles was
observed when nisin was added in a 1003 higher concentration of 1.4
mM. 50% leakage from pure DOPC vesicles was not achieved even with
a 10003 higher nisin concentration (10 mM). The CF leakage was
determined after 60 s, and the vesicle concentration was 25 mM on a Pi
basis. C, influence of anionic phospholipids on nisin Z activity. Vesicles
were made of DOPC ( l ), DOPC/DOPG (1:1) (M), and DOPG (), each
supplemented with 0.065 mol % lipid II. CF leakage was determined
after 60 s, and the vesicle concentration was 25 mM on a Pi basis. D, lipid
II concentration dependence of the nisin pore formation activity. DOPC
liposomes were supplemented with increasing amounts of lipid II and
treated with two concentrations of nisin, 10 nM nisin (E) and 100 nM
nisin ( l ).
FIG. 2. Nisin Z and [V32E]- and [V32K]nisin-induced CF leak-
age (100 nM, open bars) and K1 leakage (filled bars) from DOPC
vesicles with 0.065 mol % lipid II after 1 min.
FIG. 3. Binding behavior of radiolabeled nisin Z to vesicles
made of DOPC and complemented with 0.5 mol % lipid II. Exper-
imental data (E); theoretical data for Langmuir type binding () with
K 5 2 3 107 M21. In the theoretical analysis it was assumed that nisin
binds only to lipid II.
Lipid II-mediated Duality in the Activity of Nisin 1775
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reduced in the presence of lipid II (Fig. 5C); the concentration
necessary to release 50% of CF dropped about 75-fold from
0.015 mM (Fig. 1B) to 1.15 mM for the mutant peptide. The
concentration dependence of the pore formation by the S3T
mutant was unchanged as compared with the wild-type peptide
(Fig. 5C, parallel lines), indicating that the affinity of the
peptide for lipid II was impaired rather than its pore formation
activity. In fact, the binding constant of this mutant peptide
dropped about 50-fold to 0.043 3 107 M21. The strong effect of
the incorporation of an additional methyl group points out a
crucial role of the conformation of the N-terminal ring of nisin
in the specific binding of lipid II.
Another interesting mutant that demonstrated the impor-
tance of a correct structure of the N-terminal part of nisin is the
T13C peptide. This mutation results in the formation of a
disulfide bond instead of a thioether, which influences consid-
erably the conformation of ring C (33). Accordingly, this peptide
was almost inactive in vivo (Table I) and in the liposome assay
in the presence of lipid II (Fig. 5C). N-terminal extensions of
nisin had also been found to be detrimental to the activity of
the lantibiotic; e.g. the modified but uncleaved nisin Z precur-
sor peptide was completely inactive against M. flavus (34). A
related precursor in which the leader peptide of nisin was
exchanged for the subtilin leader segment (17) did not show
any activity against lipid II-containing liposomes as well
(Fig. 5C).
Inhibition of in Vitro Peptidoglycan Biosynthesis by Nisin
Peptides—For [S3T]nisin Z, we observed comparable reduc-
tions in its affinity for lipid II, its pore formation activity on
liposomes, and its in vivo activity. In contrast, the hinge region
mutants were completely inactive in pore formation but re-
tained comparatively high in vivo activity (Table I). Because
the residual activity e.g. of [DN20/DM21]nisin against Micro-
coccus strains or S. thermophilus was in the same range of
concentrations as the activity of mersacidin and vancomycin
(30–70 nM, Ref. 14) we speculated that the nisin hinge region
mutants could exert their antibiotic activity primarily via in-
hibition of cell wall biosynthesis. Both mersacidin and vanco-
mycin form a complex with lipid II and thereby block de novo
synthesis of polymeric peptidoglycan (14). We therefore com-
pared the inhibitory activity of nisin and of the relevant mutant
peptides in an established in vitro cell wall biosynthesis assay
(35) based on isolated E. coli membranes. The wild-type peptide
clearly inhibited the formation of polymeric peptidoglycan in a
concentration-dependent manner (Fig. 6). As expected, the
DN20/DM21 deletion mutant was fully inhibitory and may even
have a somewhat stronger effect in this assay, explaining its
relatively strong in vivo activity. In contrast, the S3T mutant
had almost no inhibitory effect, which correlates well with its
reduced affinity for lipid II and with its pore formation activity
as depicted in Fig. 5C.
DISCUSSION
In this report we have analyzed the first known case of a pore
formation mechanism by an amphiphilic antibiotic peptide that
is based on specific interaction with a defined integral compo-
nent of bacterial cytoplasmic membranes. We demonstrate that
the lantibiotic nisin binds with high affinity to the membrane-
bound bacterial cell wall precursor lipid II, which consists of
the bactoprenol-carrier lipid and the complete monomeric di-
saccharide-pentapeptide peptidoglycan subunit. The high po-
tency that derives from such a target-mediated poration may
well explain why nisin is so much more effective against bac-
teria in which the docking molecule is available for binding as
FIG. 4. Primary structure of nisin Z. The modifications of the nisin mutants used in this study are indicated by arrows. [V32E]nisin Z and
[V32K]nisin Z contain an unmodified Ser residue on position 33 instead of Dha in wild-type nisin (dotted arrow). DN20/DM21 and N20P/M21P are
modifications of nisin A. Nisin A differs from nisin Z at position 27 (His). Dha, dehydroalanine; Dhb, dehydrobutyrine; Ala-S-Ala, lanthionine;
Abu-S-Ala, b-methyllanthionine.
TABLE I
Antimicrobial activities of nisin and nisin variants determined as MIC against Micrococcus flavus and Streptococcus thermophilus
Peptide
Micrococcus flavus Streptococcus thermophilus
Activity on liposomes
nM mg/liter nM mg/liter
Nisin Z (wild type) 3.3 11 1.8 6 111
V32E 13.5 45 30.0 100 11
V32K 3.3 11 15.0 50 11
M17K 6.6 22 NDa 1
T13C .60 .20 .60 .200 2
DN20/DM21b 26.4 88 74.6 250 2
N20P/M21Pb 9.8 33 44.7 150 2
M21G 9.9 33 3.6 12 2
T2S 1.5 5 0.9 3 11
T2A 4.5 15 3.0 10 11
T2V 3.3 11 1.8 6 11
S3T 39 130 14.1 47 1
Nisin with subtilin leader .60 (.200) ND 2
a ND, not determined.
b Both hinge region mutants were constructed in the nisA genetic background.
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compared with a peptide that apparently acts in a nontargeted
fashion such as magainin 2 (5). The results reported here and
in previous papers on the molecular mechanisms of activity of
nisin in the absence of lipid II (7, 8, 18, 24, 28, 36) show that
nisin can permeabilize membranes via two different mecha-
nisms. At high concentrations (mM range) pores can be formed
without lipid II, i.e. in a target-independent fashion. For opti-
mal activity in the absence of lipid II, membranes should con-
tain 50–60% negatively charged phospholipids, and the posi-
tively charged C terminus of nisin is important for initial
binding (24) and for antimicrobial activity (18). Pores formed
under such conditions are significantly anion-selective (24); the
membrane potential supports pore formation, and the wedge
model (37) may possibly describe mechanistic details. In con-
trast, when lipid II is available, nisin can disturb the barrier
function of a bilayer already at nM concentrations and a model
taking into account features elaborated in this study is pre-
sented in Fig. 7.
Throughout this study we observed a striking correlation
between the activity of nisin in vivo and its activity against
lipid II-doped DOPC vesicles in contrast to pure DOPG or
DOPC vesicles (Fig. 1B). The most important observation in
this regard is that MIC values and the concentrations neces-
sary for activity against lipid II-containing liposomes are in the
same range, i.e. nanomolar instead of micromolar against lipid
II-free liposomes. Also, high affinity binding to a docking mol-
ecule as an initial step of the activity can explain the discrep-
ancy between the activity of some mutants on model mem-
branes and against intact bacterial cells. In this regard, the
S3T mutation as described earlier is the most clear example.
For the hinge region mutants the correlation between the dye
release activity (Fig. 5B) and the in vivo activity (Table I) was
less obvious. However, what appears to be a discrepancy at first
sight, rather highlights a unique feature of nisin that was not
identified in other antibiotics so far. The N terminus seems to
be involved in the binding of nisin to lipid II, whereas the hinge
region between ring clusters A, B, C and D, E is most important
for pore formation (as depicted in Fig. 7). Whereas peptides
mutated in this segment lose the pore formation activity, their
capacity for binding lipid II is less affected. Therefore, nisin
retains the activity to prevent lipid II incorporation into poly-
meric peptidoglycan, thus acting in a way that is analogous to
the antibiotics mersacidin and vancomycin (14). In contrast,
the S3T mutation affects initial binding to lipid II and thus
equally affects cell wall biosynthesis and the pore forming
activity.
For the charged mutants, comparison of the in vivo activity
and in vitro liposome results is complicated by the fact that the
Gram-positive cell wall is a highly charged anionic polymer
that acts as a binding matrix for polycationic peptides. Several
studies (e.g. Ref. 38) have demonstrated the importance of the
accumulation of cationic peptide antibiotics in the cell wall,
which results in highly increased local concentrations of the
peptides as compared with the surrounding media. Thus, al-
though pore forming activity of the M17K peptide is affected in
vitro, the increase in its net positive charge should lead to
higher accumulation. Increased local concentration in addition
to effective inhibition of peptidoglycan biosynthesis could ex-
plain the relatively small impact on the M17K mutant in vivo
activity. In line with this interpretation is the relatively small
effect on dye release of the introduction of either a positive or a
negative charge in position 32, which in vivo resulted in wild-
type activity when a positive charge is introduced (V32K) and
a quite significant reduction when the net positive charge is
further reduced (V32E).
The identification of a specific target enables for the first
time rational design strategies, and a clear picture for struc-
tural and functional relationships in nisin is emerging. Al-
though specific target-mediated poration may be detected more
often in the future, nisin seems to be a particular case in that
two different killing mechanisms are combined in one molecule.
For both mechanisms, structural features of the peptide and
defined segments in the molecule can now be identified. The
results convincingly demonstrate that the interaction of nisin
with lipid II is relevant in vivo at least for those bacterial
strains, which are of high or intermediate sensitivity toward
the lantibiotic. Low level sensitivity, which may start in the
FIG. 5. Activity of nisin mutant peptides on the lipid II-doped
liposomes. The CF leakage from DOPC vesicles containing 0.065 mol
% lipid II was determined after 60 s; the vesicle concentration was kept
at 25 mM on a Pi basis. A, activity of charge mutants: wild-type nisin (f),
V32E (M), V32K (), M17K (E). B, activity of hinge region mutants:
wild-type nisin (f), DN20/DM21 (), N20P/M21P (l ), M21G (E). C,
activity of N-terminal mutants: wild-type nisin (f), T2S (M), T2A (E),
T2V (), S3T (l ), T13C (), and nisin Z prepeptide with subtilin leader
(l).
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micromolar concentration range (corresponding to ;3 mg/ml)
could result from lipid II-independent activity as observed with
pure DOPG/DOPC liposomes and could explain the low activity
of nisin against microorganisms that do not contain lipid II in
their membranes, such as yeasts and fungi, as well as its low
toxicity in animal model studies (2).
Thus, the accessibility of the docking molecule may be ulti-
mately relevant for the activity of the lantibiotic. Because cell
wall biosynthesis is a tightly controlled process, and the bac-
toprenol-bound central carriers in that process are limited in
number, one can assume that these molecules are in intimate
contact with proteins involved in the membrane-associated
steps of cell wall formation. Depending on the type of interac-
tions with such proteins, the access to lipid II may be restricted2 I. Wiedemann, R. Benz, and H.-G. Sahl, unpublished observations.
FIG. 7. Model for the lipid II-mediated nisin pore formation. Based on our results, we propose that nisin first binds to the outwardly
orientated carbohydrate moiety of lipid II in a 1:1 stoichiometry. The N-terminal segment of the lantibiotic is essential for binding, and a negative
surface charge is not necessary. The C-terminal part of nisin is then assumed to translocate across the membrane, in accordance with the
translocation found in the absence of lipid II (28). For this step the flexible hinge region between ring clusters A, B, C and D, E is important. Recent
preliminary results with lipid II-doped black lipid bilayers indicated that the pore stability increases from the millisecond range to several seconds
and that the pore formation process becomes voltage-independent.2 This suggests that interactions with the lipid II moiety stabilize a conducting
transmembrane orientation of the peptides. Interactions of e-amino groups of lysine side chains with pyrophosphate groups of lipid II may be
helpful in this regard and could also explain the reduced anion selectivity of the pore. Several nisin/lipid II complexes are presumed to assemble
for a functional pore thus explaining the rapid efflux from liposomes and living cells of molecules of the size of carboxyfluorescein, amino acids, and
ATP (7). The position of the lipid moiety of lipid II in the bilayer is unknown but may be of ultimate importance for nisin pore formation; structural
details of the molecule are given in the bottom of the figure. The cartoon of nisin points out functionally important segments of the molecule; for
the complete structure of nisin see Fig. 6.
FIG. 6. Inhibition of in vitro pepti-
doglycan synthesis by nisin Z and
mutant peptides. The amount of poly-
meric peptidoglycan produced in the pres-
ence of the peptides is given relative to an
untreated control. The experiment shown
is representative of three independent
experiments.
Lipid II-mediated Duality in the Activity of Nisin1778
 at University of G
roningen on M









to such an extent that even Gram-positive bacteria could be-
come comparatively insensitive toward nisin as observed for
the genus Listeria (39). There is in fact very little knowledge on
how cell wall synthesis is functionally organized, and how
bactoprenol carriers interact with the enzymes; it is not even
clear how lipid II, in particular the bactoprenol C55 lipid tail
(Fig. 7), is embedded within the membrane, e.g. in a trans-
bilayer fashion or in between the monolayers. We consider it
realistic that the results reported here not only will form the
basis for new strategies to rationally improve nisin and related
lantibiotics, but also will enable us to address fundamental
questions about the structural organization of bacterial cell
wall biosynthesis and the underlying mechanisms by which
bacteria can become resistant to antimicrobial peptides.
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